Back to today’s briefing

Story perspectives

Editas Medicine Adjusts Earnings Forecast Amid Price Target Cuts

3/31/2025

31 2

Summary

Story summary

Editas Medicine's Q1 2025 earnings forecast has brightened, shifting from a loss of $0.73 to $0.63 per share, while the full-year estimate stands at $2.71. Despite this positive shift, analysts have lowered price targets, leading to a consensus "Hold" rating. The stock opened at $1.25, reflecting a market cap of $103.72 million, as the company continues its pioneering work in CRISPR-based genomic therapies.

1 of 1

Story summary

Editas Medicine's Q1 2025 earnings forecast has brightened, shifting from a loss of $0.73 to $0.63 per share, while the full-year estimate stands at $2.71. Despite this positive shift, analysts have lowered price targets, leading to a consensus "Hold" rating. The stock opened at $1.25, reflecting a market cap of $103.72 million, as the company continues its pioneering work in CRISPR-based genomic therapies.